PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 12, 20240 citationsOpen Access

Supplementary Figure 5 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

View Full Paper
AKAlana L. KellerUniversity of North Carolina at Chapel HillLRLauren T. ReimanUniversity of Southern CaliforniaODOlivia Perez deMedStar Georgetown University Hospital

Key Points

Key points are not available for this paper at this time.

Abstract

The percentage of MM cells CD28+ does not appear to affect sensitivity to SAR442257

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Keller et al. (2024) studied this question.

synapsesocial.com/papers/68e746dfb6db6435876c00b3https://doi.org/10.1158/2767-9764.25392852.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper